Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden

Published:2022-06-29 Issue:17 Volume:128 Page:3254-3264
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Raj Shailaja K. S.¹,Routh Eric D.²³,Chou Jeff W.⁴,Votanopoulos Konstantinos I.⁵⁶,Triozzi Pierre L.¹⁶,Miller Lance D.²⁶

Affiliation:

1. Section of Hematology and Oncology, Department of Internal Medicine Wake Forest Baptist Medical Center Winston Salem North Carolina USA

2. Department of Cancer Biology Wake Forest School of Medicine Winston Salem North Carolina USA

3. Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

4. Department of Biostatistics and Data Science Wake Forest School of Medicine Winston Salem North Carolina USA

5. Department of Surgery, Division of Surgical Oncology Wake Forest Baptist Medical Center Winston Salem North Carolina USA

6. Wake Forest Baptist Comprehensive Cancer Center Winston Salem North Carolina USA

Funder

National Cancer Institute

Comprehensive Cancer Center at Wake Forest Baptist Medical Center

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34333

Reference50 articles.

1. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

2. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma

3. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

4. Lessons from Coley's Toxin

5. A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3